Eli Lilly and Company (LLY)
| Market Cap | 710.90B |
| Revenue (ttm) | 34.12B |
| Net Income (ttm) | 5.24B |
| Shares Out | 950.77M |
| EPS (ttm) | 5.80 |
| PE Ratio | 128.25 |
| Forward PE | 59.15 |
| Dividend | $5.20 (0.69%) |
| Ex-Dividend Date | Feb 14, 2024 |
| Volume | 1,373,427 |
| Open | 751.68 |
| Previous Close | 750.77 |
| Day's Range | 743.00 - 753.00 |
| 52-Week Range | 367.35 - 800.78 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 714.14 (-4.59%) |
| Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $714.14, which is a decrease of -4.59% from the latest price.
News
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that...
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s...
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...
Cramer says stocks that pulled back Tuesday still 'have everything going for them'
CNBC's Jim Cramer reviewed Tuesday's market action, saying stocks that saw losses like Nvidia and Eli Lilly remain winners.
Wegovy's heart benefits are not just linked with weight loss, new study suggests
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord...
Outperforming ETF manager names a potential ‘50-bagger' in the stock market
The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-ma...
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne...
Top three US healthcare stocks to buy in April
As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health. 1. Lilly (Eli) & Co.
Why There's Limited Supply Of The Weight Loss Drug Zepbound
Zepound—an Eli Lilly-produced drug that has become a popular alternative to other weight loss drugs such as Wegovy and Ozempic—is facing a shortage in the U.S. of some of its doses because of the grow...
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Lilly's weight-loss drug Zepbound to face supply crunch through April-end, US FDA says
Two doses of Eli Lilly's weight-loss drug Zepbound are expected to remain in short supply through April-end, the U.S. Food and Drug Administration's website showed on Wednesday, as demand for the powe...
Biotech's Next Gold Rush: Weight-Loss Drugs
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
Some doses of Lilly's Mounjaro in tight supply through April, US FDA says
Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website showed.
Eli Lilly's Ozempic Competitors Face Risks. Why the Stock Has More Upside.
Citi analyst Andrew Baum raised his price target on Lilly stock to $895 from $675, citing increased sales expectations for a new drug.
Three-Stock Lunch: Meta, Disney, and Eli Lilly
Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss plays for three stocks, including Meta Platforms, Disney, and Eli Lilly.
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina...
Here's how much people are willing to spend on weight loss drugs, according to a new survey
Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.
Medicare allows coverage of Wegovy for heart patients
Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new ...
Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan Seigerman
Evan Seigerman, BMO Capital, joins 'Fast Money' to discuss BMO's inaugural GLP-1 conference.
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.